Business Description
Vicore Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing treatments for serious lung diseases. Its lead drug candidate, Buloxibutid, is taken orally and is currently being tested in clinical trials for idiopathic pulmonary fibrosis and pulmonary hypertension. The company is also working on Almee, a medical device designed to support the mental wellbeing of patients living with pulmonary fibrosis, alongside a digital app for lung disease patients developed in partnership with Alex Therapeutics. Founded in 2000 and based in Stockholm, Vicore collaborates with several partners to advance next-generation treatments targeting the same biological pathway as its lead compound.
